← Leaderboards
Taneli Jouhikainen
Savara, Inc.
$4,415,173
Attributed
$4,510,349
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2011–15$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,510,349 · 4
By mechanism
R44$3,986,098 · 1
R43$333,898 · 2
U43$190,353 · 1
Top collaborators
- Masaaki Tamura1 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchDevicesParticleTechnologyPerformanceChronicDrug FormulationsLungPowder Dose FormExcipientsBreathingPharmaceutical PreparationsInhalatorsDoseCystic Fibrosis PatientsAerosolsHome EnvironmentCystic FibrosisAntibioticsDesignHospital AdministrationEnsureBronchopneumoniaClinical Data
Grant awards (6)
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$1,015,080
R44 · FY2015 · HL · contact PI
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$1,680,649
R44 · FY2014 · HL · contact PI
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$1,290,369
R44 · FY2013 · HL · contact PI
Targeted nanoparticle gene therapy for lung cancer$190,353
U43 · FY2013 · CA · contact PI
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF$149,750
R43 · FY2012 · HL · contact PI
A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use$184,148
R43 · FY2011 · AI · contact PI